+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Expression of serum insulin-like growth factors, insulin-like growth factor-binding proteins, and the growth hormone-binding protein in heterozygote relatives of Ecuadorian growth hormone receptor deficient patients



Expression of serum insulin-like growth factors, insulin-like growth factor-binding proteins, and the growth hormone-binding protein in heterozygote relatives of Ecuadorian growth hormone receptor deficient patients



Journal of Clinical Endocrinology and Metabolism 74(4): 743-750



Recently, an isolated population of apparent GH-receptor deficient (GHRD) patients has been identified in the Loja province of southern Ecuador. These individuals presented many of the physical and biochemical phenotypes characteristic of Laron-Syndrome and are believed to have a defect in the GH-receptor gene. In this study, we have compared the biochemical phenotypes between the affected individuals and their parents, considered to be obligate heterozygotes for the disorder. Serum GH, insulin-like growth factor I and II (IGF-I and IGF-II) levels were measured by RIA Insulin-like growth factor binding proteins. (IGFBPs) were measured by Western ligand blotting (WLB) of serum samples, following separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and relative quantitation of serum IGFBPs was performed with a scanning laser densitometer. Serum GH-binding protein (GHBP) levels were measured with a ligand-mediated immunofunctional assay using a monoclonal antibody raised against the GHBP. These values were then compared to values obtained from normal, sex-matched adult Ecuadorian controls, to determine if the above parameters were abnormal in the heterozygotes. The serum IGF-I levels of the GHRD patients were less than 13% of control values for adults and 2% for children. However, the IGF-I levels of both the mothers and fathers were not signficantly different from that of the control population. The serum IGF-II levels of the GHRD patients were approximately 20% of control values for adults and 12% for the children. The IGF-II levels of the mothers were reduced, but were not significantly different from that of the control population. However, IGF-II levels of the fathers were significantly lower than those of controls (64% of control male levels). WLB analysis of serum IGFBP levels of the affected subjects demonstrated increased IGFBP-2 and decreased IGFBP-3, suggesting an inverse relationship between these IGFBPs. The GHRD patients who had the lowest serum IGFBP-3 levels (as measured by WLB) demonstrated a serum protease activity that could proteolyze 125I-IGFBP-3. GHRD patients who had higher serum IGFBP-3 levels lacked this serum protease activity. There were no differences in the serum IGFBP profiles of the mothers or the fathers for either IGFBP-2 or IGFBP-3, and serum from both groups lacked the ability to significantly proteolyze 125I-IGFBP-3. While GHRD patients had very low levels of serum GHBP, some patients did have measurable GHBP levels. The mean GHBP levels of the mothers (76% of control females) and father (64% of control males), while reduced, did not significantly differ from those of controls. Thus, while serum IGF-II and GHBP levels were somewhat reduced in the parents of the GHRD patients, they do not appear to provide a reliable biochemical marker for heterozygosity of the defective gene.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040109421

Download citation: RISBibTeXText

PMID: 1372321

DOI: 10.1210/jcem.74.4.1372321


Related references

Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metabolism: Clinical and Experimental 53(12): 1565-1573, 2004

Insulin-like growth factors and their binding proteins in patients with growth hormone receptor deficiency: suggestions for new diagnostic criteria. The Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatrica . Supplement 383: 125-126, 1992

Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatrica . Supplement 388: 40, 1993

Effects of growth hormone and pregnancy on expression of growth hormone receptor, insulin-like growth factor-I, and insulin-like growth factor binding protein-2 and -3 genes in bovine uterus, ovary, and oviduct. Biology of Reproduction 55(5): 996-1002, 1996

Growth hormone therapy in adult patients with growth hormone deficiency Dose-dependent effects on insulin-like growth factors and insulin-like growth factor binding protein-3. Acta Endocrinologica 128(Suppl. 2): 75, 1993

Regulation of serum insulin-like growth factors and their binding proteins in Ecuadorean patients with growth hormone receptor dysfunction (growth hormone insensitivity). Acta Paediatrica Scandinavica. Supplement 377: 104-109, 1991

Insulin-like growth factor binding proteins-2 and -3 in Ecuadorian patients with growth hormone receptor deficiency and their parents. Laron, Z, Parks, J S Pediatric and Adolescent Endocrinology; Lessons from Laron Syndrome (LS) 1966-1992: A model of GH and IGF-1 action and interaction: 185-191, 1993

The composition and distribution of insulin-like growth factors and IGF-binding proteins in the serum of growth hormone receptor-deficient patients Effects of IGF-I therapy on IGFBP-3. Journal of Clinical Endocrinology & Metabolism 77(6): 1683-1689, 1993

Serum concentrations of insulin-like growth factors (IGFs), IGF binding proteins 1 and 3 and growth hormone binding protein in obese women and the effects of growth hormone administration: a double-blind, placebo-controlled study. European Journal of Endocrinology 133(1): 65-70, 1995

Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during menstrual cycle. Human Reproduction 12(10): 2123-2128, 1997

Changes in serum concentrations of growth hormone, insulin, insulin- like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Human Reproduction 12(10): 2123-2128, 1997

Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Human Reproduction 12(10): 2123-2128, 1997

Dose-dependent responses in insulin-like growth factors, insulin-like growth factor-binding protein-3 and parameters of bone metabolism to growth hormone therapy in young adults with growth hormone deficiency. Hormone Research 43(6): 249-256, 1995

Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. Journal of Medical Case Reports 4: 305, 2010

The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3. Journal of Clinical Endocrinology and Metabolism 77(6): 1683-1689, 1993